ArticleBMC public health2026
Hepatitis B in China: the analysis of mortality and burden of disease trends from 2008 to 2021.
Article in BMC public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo characterize mortality patterns and trends, we systematically examined temporal trends and population disparities in hepatitis B mortality and disease burden among Chinese residents from 2008 to 2021.
methodsMortality data for hepatitis B were obtained from the Disease Surveillance Points (DSP) system compiled by the Chinese Center for Disease Control and Prevention (China CDC), covering the period 2008–2021. We used Microsoft Excel to calculate the crude mortality rate (CMR), age-specific mortality rates, age-standardized mortality rate (ASMR), potential years of life lost (PYLL), and the potential years of life lost rate (PYLLR). The Joinpoint software was used to estimate the annual percentage change (APC) for each time period and the average annual percentage change (AAPC) for the entire period. We used R to perform a chi-square (χ²) test and assess the comparability of AAPC between groups. The impact of age, period, and cohort on hepatitis B mortality was assessed using an online age-period-cohort analysis tool.
resultsCompared to 2008, the ASMR and PYLLR of hepatitis B in China decreased significantly in 2021, exhibiting a regional pattern of “higher in the west and lower in the east.” Overall, from 2008 to 2021, the national AAPC value for hepatitis B ASMR was − 4.53%, and the national AAPC value for hepatitis B PYLLR was − 4.71%. Gender differences showed that both ASMR and PYLLR were higher in men than in women. Urban-rural differences showed that rural areas consistently had higher values than urban areas. Regional differences showed that the western region > central region > eastern region. In addition, the elderly population and those with earlier birth cohorts had higher ASMR and PYLLR values.
conclusionsFrom 2008 to 2021, hepatitis B-related mortality and premature mortality burden in China declined substantially, indicating sustained progress in hepatitis B prevention and management. However, marked disparities persist across regions, urban-rural settings, sex, and age groups, highlighting the need for targeted strategies focusing on high-burden populations to further reduce inequalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.